Caribou Biosciences Inc (CRBU) |
|
Price: $5.3700
$0.01
0.187%
|
Day's High:
| $5.47
| Week Perf:
| -25.62 %
|
Day's Low: |
$ 5.25 |
30 Day Perf: |
-21.03 % |
Volume (M): |
2,688 |
52 Wk High: |
$ 8.59 |
Volume (M$): |
$ 14,434 |
52 Wk Avg: |
$5.43 |
Open: |
$5.28 |
52 Wk Low: |
$3.44 |
|
|
Market Capitalization (Millions $) |
397 |
Shares
Outstanding (Millions) |
74 |
Employees |
- |
Revenues (TTM) (Millions $) |
34 |
Net Income (TTM) (Millions $) |
-102 |
Cash Flow (TTM) (Millions $) |
-7 |
Capital Exp. (TTM) (Millions $) |
12 |
Caribou Biosciences Inc
Caribou Biosciences Inc. is a biotechnology company that specializes in developing CRISPR-Cas9 gene editing technology. The company was founded in 2011 by Jennifer Doudna, Martin Jinek, Rachel Haurwitz, and Erik Sontheimer. Caribou Biosciences is headquartered in Berkeley, California.
The company focuses on leveraging CRISPR-Cas9 technology to enable precise and efficient gene editing in various applications, including therapeutics, agriculture, and industrial biotechnology. Caribou Biosciences offers a range of tools and services for genome engineering and is committed to providing reliable and scalable solutions.
Caribou Biosciences collaborates with academic institutions, pharmaceutical companies, and other partners to develop innovative treatments for genetic diseases, improve crop traits, and enhance bioproduction processes. The company's expertise in CRISPR-Cas9 has gained significant recognition within the scientific community, making Caribou Biosciences a leading player in the field of gene editing technology.
Company Address: 2929 7th Street Berkeley 94710 CA
Company Phone Number: 982-6030 Stock Exchange / Ticker: NASDAQ CRBU
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Caribou Biosciences Inc
Caribou Biosciences, a leading biotechnology company focused on genome engineering, has recently announced the appointment of Tim Kelly as its Chief Technology Officer (CTO). This strategic move emphasizes Caribou's commitment to advancing its technical operations strategy and execution. With this appointment, Caribou aims to fortify its position as a frontrunner in the field of genome engineering and further strengthen its research and development capabilities. Furthermore, Caribou Biosciences has exciting clinical catalysts lined up for 2024, which hold great promise for the treatment of patients suffering from various diseases. One of the notable developments is the Phase 1 trial data expansion of CB-010 ANTLER, where the company aims to disclose initial dose expansion data as well as the Recommended Phase 2 Dose (RP2D) in the second quarter of 2024. This trial will play a significant role in assessing the safety and efficacy of CB-010 ANTLER, a potential breakthrough in the field of genome engineering.
|
Clinical Study
Published Sun, Jan 7 2024 4:00 PM UTC
Abstract:This article discusses the recent appointment of Tim Kelly as the Chief Technology Officer (CTO) of Caribou Biosciences, a leading biotechnology company focused on genome engineering. Additionally, it highlights significant clinical catalysts expected in 2024, including the Phase 1 trial data expansion of CB-010 ANTLER and the company's plans for a Phase 3 pivotal t...
|
Caribou Biosciences Inc
In the competitive world of biotechnology, Caribou Biosciences Inc has made significant progress in its most recent fiscal period, demonstrating encouraging signs of recovery. The company's financial results reveal improvements in several key areas, including earnings per share (EPS), revenue growth, and reduced net losses. The positive trend is further supported by a surge in share prices over the past five trading days, indicating growing investor confidence. However, while there is reason for optimism, it is crucial to examine these results within the broader context of Caribou Biosciences Inc's overall financial position. Financial Performance Analysis: Caribou Biosciences Inc's financial performance in its most recent fiscal period showcased a remarkable decrease in loss per share, indicating an improvement in profitability. The company narrowed its loss to $-0.12 per share, compared to $-0.44 per share in the same period last year. Sequentially, EPS grew by 530.146%, rising from $-0.48 per share to the current level. This upward trend in EPS reflects Caribou Biosciences Inc's ability to optimize its operations and generate better-performing outcomes.
|
Caribou Biosciences Inc
Caribou Biosciences Inc Shows Promising Signs of Growth Despite Challenging Financial Results Caribou Biosciences Inc, a leading biotechnology company, recently released its financial results for the April to June 30, 2023, span. While the numbers may seem discouraging at first glance, there are several factors that indicate a positive outlook for the company's future. One of the key points to note is the increase in the deficit per share. Although the deficit per share increased from $-0.44 to $-0.48 compared to a year ago, it is crucial to consider the overall context. In the previous reporting period, the deficit per share stood at $-0.46, signifying a marginal improvement. This suggests that Caribou Biosciences Inc is effectively managing its finances and making progress towards reducing the deficit.
|
Caribou Biosciences Inc
Caribou Biosciences Inc, commonly referred to as CRISPR or Caribou, is a biotechnology company founded in 2011 that specializes in gene editing and genetic engineering. The company is headquartered in Berkeley, California, and has a presence in the US and Europe, including in London and Paris. Caribou Biosciences Inc has been in the news for its revolutionary gene editing technology that allows for scientists to precisely modify the DNA of living organisms, including humans, animals, and plants. The technique is called CRISPR-Cas9, and it is a game-changer in genetic research due to its affordability, efficiency, and precision.
|
Per Share |
Current |
Earnings (TTM) |
-1.37 $ |
Revenues (TTM) |
0.47 $
|
Cash Flow (TTM) |
- |
Cash |
4.45 $
|
Book Value |
4.98 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-1.37 $
|
Revenues (TTM) |
0.47 $ |
Cash Flow (TTM) |
- |
Cash |
4.45 $
|
Book Value |
4.98 $ |
Dividend (TTM) |
0 $ |
|
|
|
|